Quantitative immuno-positron emission tomography imaging of HER2-positlve tumor xenografts with an iodine-124 labeled anti-HER2 diabody

Cancer Research

Volumn 65, Issue 4, 2005, Pages 1471-1478

  Robinson, Matthew K ^a   Doss, Mohan ^a   Shaller, Calvin ^a   Narayanan, Deepa ^a   Marks, James D ^b   Adler, Lee P ^b   González Trotter, Dinko E ^c   Adams, Gregory P ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GE Global Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COTRANSPORTER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IODINE 124; PROTEIN TYROSINE KINASE; RADIOACTIVE IODINE; TRACER; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; CANCER; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIODINATION; TUMOR XENOGRAFT;

ANIMALS; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 13944266719     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2008     Document Type: Article

References (38)

1. Jain M, Batra SK. Genetically engineered antibody fragments and PET imaging: a new era of radioimmunodiagnosis. J Nucl Med 2003;44:1970-2.
2. Russeva MG, Adams GP. Radioimmunotherapy with engineered antibodies. Expert Opin Biol Ther 2004;4:217-31.
3. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465-74.
4. Goldenberg DM, Goldenberg H, Sharkey RM, et al. Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTc. Cancer Res 1990;50:909-21s.
5. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-93.
6. Bakir MA, Eccles S, Babich JW, et al. C-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992;33:2154-60.
7. 124I-labeled monoclonal antibodies. Gynecol Oncol 1993;48:61-7.
8. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003;44:1663-70.
9. Adams GP. Improving the tumor specificity and retention of antibody-based molecules. In vivo 1998;12:11-22.
10. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a Copper-64-labeled engineered antibody fragment Proc Natl Acad Sci U S A 2000;97:8495-500.
11. Yazaki PJ, Wu AM, Tsai SW et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments. Bioconjug Chem 2001;12:220-8.
12. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
13. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405-12.
14. Schier R, Marks JD, Wolf E, et al. In vitro and in vivo characterization of a human anti-c-erbB2 single chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995;1:73-81.
15. Parker CW. Radiolabeling of proteins. In: Deutscher MP, editor. Methods in enzymology. San Diego: Academic Press; 1990. p. 721-37.
16. Adams GP, Schier R. Developing anti-HER2/neu single-chain Fv fragments from phage display libraries. In: Bartlett J, editor. Methods in molecular medicine. Totowa (NJ): The Humana Press; 2000. p. 729-47.
17. Adams GP, McCartney JE, Tai M-S, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-34.
18. Adams GP, McCartney JE, Wolf EJ, et al. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J Nucl Med 1995;36:2276-81.
19. 124I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004;45:1237-44.
20. Wu AM, Williams LE, Zieran L, et al. Anticarcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 1999;4:1-12.
21. Carasquillo JA. Radioimmunoscintigraphy with polyclonal and monoclonal antibodies. In: Zalutsky MR, editor. Antibodies in radiodiagnosis and therapy. Boca Raton: CRC Press; 1989. p. 169-98.
22. Bolton AE, Hunter WM. The labeling of proteins to high specific radioactivities by conjugation to an I-125-containing acylating agent Biochem J 1973;133:529-39.
23. Wilbur DS, Hadley SW, Hylarides MD, et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med 1989;30:216-26.
24. Vaidyanathan G, Affleck DJ, Zalutsky MR. Radioiodination of proteins using n-succinimidyl 4-hydroxy-3-iodobenzoate. Bioconjug Chem 1993;4:78-84.
25. deFazio A, Chiew YE, Sini RL, et al. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000;87:487-98.
26. Brodowicz T, Kandioler D, Tomek S, et al. Anti-HER-2/neu antibody induces apoptosis in HER-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer 2001;85:1764-70.
27. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1-93S.
28. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-14.
29. Larson SM. Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med 1994;35:1653-5.
30. Raben D, Buchsbaum DJ, Khazaeli MB, et al. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther 1996;3:567-80.
31. 124I-cdr-grafted humanized A33 monoclonal antibody. J Nucl Med 2001;42:764-9.
32. Adams GP, Shaller CC, Chappel L, et al. Delivery of the α-emitting radioisotope Bi-213 to tumors via single-chain and diabody molecules. Nucl Med and Biol 2000;27:339-46.
33. Kabat EA, Wu TT, Reid-Miller M, et al. Sequences of proteins of immunological interest, 5th ed. U.S. Department of Health and Human Services. Washington (DC): U.S. Government Printing Office, 1991.
34. Schier R, McCall A, Adams GP, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996;263:551-67.
35. Olafsen T, Cheung C, Yazaki PJ, et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Engineering, Design and Selection 2004;17:21-7.
36. Tatsumi M, Nakamoto Y, Traughber B, et al. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer Res 2003;63:6252-7.
37. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncology 1998;16:2659-71.
38. Slamon DJ, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/mbc) markedly increased anticancer activity: a randomized, multinational controlled phase III trial. in ASCO. 1998.